Creating Valuable Education for the Hematology/Oncology Fellow With Ronak Mistry, DO, and Vivek Patel, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Creating Valuable Education for the Hematology/Oncology Fellow: Ronak Mistry and Vivek Patel At the 2022 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Dr. Ronak Mistry and Dr. Vivek Patel, Clinical Fellows in Medicine at Vanderbilt University and hosts of The Fellow on Call podcast. Dr. Mistry and Dr. Patel share their passion for creating education geared towards fellows and the valuable experience of attending ASH as a trainee.  
Dynamic Risk Classification of Patients With Smoldering Multiple Myeloma With Luis Gerardo Rodríguez-Lobato, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Dynamic Risk Classification of Smoldering Myeloma With Luis Gerardo Rodríguez-Lobato, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Luis Gerardo Rodríguez-Lobato, MD, PhD, Specialist in Hematopoietic Stem Cell Transplant and Researcher at the Hospital Clínic de Barcelona and barnaclínic+, sat down with Oncology Data Advisor to discuss his research regarding dynamic risk classification for patients with smoldering multiple myeloma and how such a strategy can help clinicians predict the course of disease.  
Understanding Multiple Myeloma Treatment Patterns and Sequencing With Robert Rifkin, MD, FACP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Understanding Multiple Myeloma Treatment Patterns and Sequencing With Robert Rifkin, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, Medical Oncologist and Hematologist at Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss the research that he presented, titled Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry.  
Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD Recently, Dr. Noopur Raje, Director of the Center for Multiple Myeloma at Massachusetts General Hospital, sat down with Oncology Data Advisor at the 64th American Society of Hematology (ASH) Annual Meeting to disc...
Investigating CAR T-Cell Therapy Wait Time and High-Risk Disease Definitions in Myeloma With Samer Al Hadidi, MD, MS, FACP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Investigating CAR T Wait Time and High-Risk Myeloma Definitions With Samer Al Hadidi, MD, MS, FACP At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas, sat down with Oncology Data Advisor to discuss the multiple myeloma research that he presented. Dr. Al Hadidi elaborates on his studies regarding the wait list for patients who are eligible to receive chimeric antigen receptor (CAR) T-cell therapy and the variability of definitions of high-risk disease in myeloma clinical trials.  
Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Exploring Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer: Josep Tabernero, MD, PhD At the recent American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  
Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, the Director of Research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai, New York, sat down with Oncology Data Advisor to discuss his presentation regarding the phase 1/2 results of the MonumenTAL-1 study. This study researches the possible benefit of talquetamab, a bispecific antibody, in patients with relapsed or refractory multiple myeloma.  
Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Luke Walker, Chief Medical Officer of Harpoon Therapeutics, sat down with Oncology Data Advisor to discuss the results of a phase 1 trial of HPN217, a B-cell maturation antigen (BCMA)–targeting T-cell engager, which were presented at the meeting. Dr. Walker delves into the efficacy that HPN217 demonstrated in patients with relapsed/refractory multiple myeloma, including its tolerability and low risk of cytokine release syndrome (CRS).  
Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD At the recent American Society of Hematology (ASH) Annual Meeting, Kelsey Natsuhara, MD, a Fellow in Hematology and Oncology at the University of California, San Francisco, sat down with Oncology Data Advisor and ConveyMED to discuss...
Multiple Myeloma Trials and Quality News Reporting With Manni Mohyuddin, MBBS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · ASH 2022 Conversations on Multiple Myeloma (Part 1) With Manni Mohyuddin, MBBS At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Manni Mohyuddin, Assistant Professor at the University of Utah Huntsman Cancer Institute, sat down with Oncology Data Advisor to discuss the multiple myeloma research he was involved with at this year's meeting. Dr. Mohyuddin elaborates on his abstracts regarding the prognostic value of (11;14) translocation in multiple myeloma, the characterization of survival end points in clinical trials, and ways to improve the quality of news reporting of oncology clinical trials.  
Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD
Keira Smith
Expert Analysis
At this weekend's American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  
Additional Advances in Acute Leukemia Research and Clinical Trials: Amir Fathi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Acute Leukemia Research and Clinical Trials: Amir Fathi, MD In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School and Program Director of the Center for Leukemia at Massachusetts General Hospital, served as faculty for Therapy of Acute B-Cell Leukemia: An Evolving Treatment Landscape, a session presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia.
Additional Advances in Squamous Non–Small Cell Lung Cancer Research and Clinical Trials With Mark Kris, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Squamous NSCLC Research and Clinical Trials With Mark Kris, MD In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.
Additional Advances in Squamous Non–Small Cell Lung Cancer Research and Clinical Trials With Mark Kris, MD
Keira Smith
Expert Analysis
In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.  
Pioneering the Field of Stem Cell Biology With Irving Weissman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Pioneering the Field of Stem Cell Biology With Irving Weissman, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  
Additional Advances in Acute Leukemia Research and Clinical Trials With Amir Fathi, MD
Keira Smith
Expert Analysis
In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School and Program Director of the Center for Leukemia at Massachusetts General Hospital, served as faculty for Therapy of B-Cell Acute Lymphoblastic Leukemia (ALL): an Evolving Landscape, a session presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia.  
Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.
Pioneering the Field of Stem Cell Biology With Irving Weissman, MD
Keira Smith
Expert Analysis
At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  
Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD
Keira Smith
Expert Analysis
Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.  
Uncovering Racial Disparities Experienced in Breast Cancer Patients With Yara Abdou, MD
Lyn Brook
Expert Analysis
At the recent San Antonio Breast Cancer Symposium (SABCS), Yara Abdou, MD, Assistant Professor of Hematology and Oncology and Medical Oncologist at The University of North Carolina School of Medicine, presented her team's research on the disparities that Black women with breast cancer experience. Afterwards, she spoke with Oncology Data Advisor to ...

Copyright © Oncology Data Advisor. All rights reserved.